EpigeneticTX to Present Preclinical Data of EPI-003, an Epigenome Editing Therapy for Functional Cure of Chronic Hepatitis B, at EASL 2024

Shanghai, China, May 10, 2024 — Epigenic Therapeutics, Inc., a cutting-edge biotechnology company dedicated to treating various diseases through epigenetic regulation and developing next-generation epigenetic therapies, announced that it will deliver an oral presentation at the 2024 European Association for the Study of the Liver (EASL) Congress held in Milan, Italy, from June 5 to 8, 2024. The presentation is titled "Efficient and Heritable Elimination of HBV Viral Antigens In Vivo Using Epigenetic Gene Editing."

Epigenic is a pioneering biotechnology company dedicated to developing next-generation epigenetic regulation technologies for the treatment of chronic diseases. Compared with traditional gene editing tools that cut DNA, Epigenic's unique EPIREG™ technology offers a completely different solution. Through precise DNA methylation and histone modification, EPIREG™ can silence target genes efficiently and durably, providing revolutionary and innovative treatment options for patients with chronic diseases. Importantly, this solution will effectively address safety concerns associated with traditional gene editing.

The company will report the preclinical research progress of EPI-003, a drug developed based on the EPIREG™ technology platform. As an HBV antiviral agent, EPI-003 can specifically and simultaneously block the transcription of HBV cccDNA and HBV DNA integrated into the host genome, ultimately leading to the elimination of HBsAg and inducing serological conversion. Experimental data from human primary hepatocytes and animal models infected with HBV show that EPI-003 has the potential to be a first-in-class and best-in-class anti-HBV drug, offering hope for achieving clinical functional cure in patients with chronic hepatitis B infection.

Epigenic is a cutting-edge biotechnology company dedicated to treating various diseases through epigenetic regulation and developing next-generation gene editing therapies. Founded in 2021 by a group of scientists specializing in gene editing technology and seasoned experts from the pharmaceutical development industry, the company has established a pipeline of multiple candidate products covering metabolic diseases, cardiovascular conditions, viral hepatitis, ophthalmology, and rare diseases. For more information, please visit: www.epigenictx.com

Business Cooperation:Partnering@epigenictx.com

Public Relations:Media@epigenictx.com

Investor Relations:Investors@epigenictx.com